Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:FBRX NASDAQ:SAGE NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$20.33+1.0%$23.31$12.21▼$40.70$563.58M-0.2456,645 shs322,607 shsFBRXForte Biosciences$11.00-2.0%$11.22$4.11▼$28.68$139.62M2.9173,170 shs177,688 shsSAGESage Therapeutics$8.68$8.90$4.62▼$11.44$543.54M0.263.63 million shsN/ASVRASavara$3.28+0.3%$2.59$1.89▼$4.70$565.18M0.41.39 million shs744,165 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+0.99%+0.54%-18.61%-9.44%-44.71%FBRXForte Biosciences-2.05%-3.76%+7.95%+30.95%+3,457.57%SAGESage Therapeutics0.00%0.00%0.00%+33.54%+9.87%SVRASavara+0.31%+3.80%+28.13%+43.23%-22.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio1.8953 of 5 stars3.40.00.00.02.32.50.6FBRXForte Biosciences2.7108 of 5 stars3.53.00.00.02.61.70.6SAGESage Therapeutics3.631 of 5 stars2.05.00.04.11.91.70.6SVRASavara2.2798 of 5 stars3.40.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$46.13126.88% UpsideFBRXForte Biosciences 3.00Buy$68.00518.18% UpsideSAGESage Therapeutics 1.93Reduce$7.85-9.56% DownsideSVRASavara 2.83Moderate Buy$6.1788.01% UpsideCurrent Analyst Ratings BreakdownLatest FBRX, ANAB, SVRA, and SAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.008/12/2025ANABAnaptysBioUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $20.008/7/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $45.007/24/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $80.007/8/2025SAGESage TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.206/24/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.006/20/2025SAGESage TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M6.24N/AN/A($1.60) per share-12.71FBRXForte BiosciencesN/AN/AN/AN/A$7.93 per shareN/ASAGESage Therapeutics$41.24M13.18N/AN/A$5.89 per share1.47SVRASavaraN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)SAGESage Therapeutics-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%11/4/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest FBRX, ANAB, SVRA, and SAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million7/30/2025Q2 2025SAGESage Therapeutics-$0.96-$0.79+$0.17-$0.79$16.69 million$31.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22FBRXForte BiosciencesN/A11.7411.74SAGESage TherapeuticsN/A9.169.13SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AFBRXForte Biosciences77.63%SAGESage Therapeutics99.22%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%FBRXForte Biosciences5.90%SAGESage Therapeutics5.50%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableSVRASavara20172.84 million163.63 millionOptionableFBRX, ANAB, SVRA, and SAGE HeadlinesRecent News About These CompaniesWellington Management Group LLP Trims Stock Position in Savara Inc. $SVRAAugust 30 at 4:13 AM | marketbeat.comSavara Announces Participation in Upcoming Investor Healthcare ConferencesAugust 26, 2025 | businesswire.comSavara Inc. (SVRA) Upgraded to Buy After FDA CMC BreakthroughAugust 24, 2025 | finance.yahoo.comSavara to Present Key Research on Rare Lung Disease at ERS Congress 2025August 24, 2025 | msn.comSavara Inc. (SVRA) Upgraded to Buy After FDA CMC BreakthroughAugust 23, 2025 | insidermonkey.comNew England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)August 22, 2025 | finance.yahoo.com3 Best Stocks to Buy Now, 8/22/2025, According to Top AnalystsAugust 22, 2025 | msn.comNew England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)August 20, 2025 | businesswire.comSavara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP ...August 19, 2025 | dutchnews.nlDSavara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by BrokeragesAugust 19, 2025 | americanbankingnews.comSavara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025August 18, 2025 | businesswire.comSavara (NASDAQ:SVRA) Shares Gap Up Following Analyst UpgradeAugust 17, 2025 | marketbeat.comSavara (NASDAQ:SVRA) Given New $6.00 Price Target at OppenheimerAugust 17, 2025 | marketbeat.comSavara (NASDAQ:SVRA) Upgraded at HC WainwrightAugust 17, 2025 | marketbeat.comSavara (NASDAQ:SVRA) Stock Price Up 8% - Should You Buy?August 16, 2025 | marketbeat.comHC Wainwright & Co. Upgrades Savara (SVRA)August 16, 2025 | msn.comSavara (NASDAQ:SVRA) Releases Earnings Results, Misses Expectations By $0.02 EPSAugust 15, 2025 | marketbeat.comSavara upgraded to Buy from Neutral at H.C. WainwrightAugust 15, 2025 | msn.comH.C. Wainwright upgrades Savara to Buy on resubmission prospectsAugust 15, 2025 | msn.comSavara upgraded at H.C. Wainwright on potential refiling of marketing applicationAugust 15, 2025 | msn.comSavara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from AnalystsAugust 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBRX, ANAB, SVRA, and SAGE Company DescriptionsAnaptysBio NASDAQ:ANAB$20.33 +0.20 (+0.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$19.85 -0.48 (-2.36%) As of 08/29/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Forte Biosciences NASDAQ:FBRX$11.00 -0.23 (-2.05%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$11.01 +0.01 (+0.08%) As of 08/29/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Sage Therapeutics NASDAQ:SAGE$8.68 0.00 (0.00%) As of 07/31/2025Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Savara NASDAQ:SVRA$3.28 +0.01 (+0.31%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.28 +0.01 (+0.15%) As of 08/29/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
